Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1550

2.
5.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
7.

Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.

Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.

Diabetes Obes Metab. 2007 Jan;9(1):103-13.

PMID:
17199725
8.
9.
10.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
11.
12.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
13.

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.

PMID:
17355742
15.

[Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen].

Bu S, Guo XH, Yang WY, Lu GZ, Yang ZJ, Ren TT, Gao Y.

Zhonghua Yi Xue Za Zhi. 2007 Nov 27;87(44):3115-8. Chinese.

PMID:
18269868
16.

Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.

Chen J, Alemao E, Yin D, Cook J.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:33-42. doi: 10.1111/j.1463-1326.2008.00885.x.

PMID:
18435672
17.

Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.

Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:8-15. doi: 10.1111/j.1463-1326.2008.00881.x.

PMID:
18435669
18.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
19.

Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):194-202.

PMID:
17414590
20.

Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.

Janka HU, Högy B.

Eur J Health Econ. 2008 May;9(2):165-70. Epub 2007 May 26.

PMID:
17530309
Items per page

Supplemental Content

Write to the Help Desk